ArticleNature medicine2023
The German Network for Personalized Medicine to enhance patient care and translational research.
Abstract readLetter
In one paragraph
Article in Nature medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed, 1 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Molecular Tumor Boards clinical impact on patient care and structural features: A systematic review and meta-analysis.PLoS medicine · 2026Pooled it
- Genomic Medicine Sweden: Advancing precision medicine at the national level.Journal of internal medicine · 2026Review
- Review
- Molecular tumor board-guided osimertinib therapy in EGFR L858R/Q701L-mutant lung adenocarcinoma supported by functional validation.The oncologist · 2026Article
- LLM-Generated Lay-Language Protocols for Molecular Tumor Board Patients: Evaluation of Quality and Clinical Usability.Journal of medical Internet research · 2026Article
- From Recommendation to Implementation: Clinical Outcomes of a Single-Center Molecular Tumor Board.Targeted oncology · 2026Article
- Precision oncology's translation gap-Can molecular tumor boards bridge it?PLoS medicine · 2026Article
- Implementing whole genome and transcriptome sequencing for cancer patients in routine healthcare: a comprehensive guide to costing.British journal of cancer · 2026Article
- Time dependent outcomes modeling in a real-world analysis of the molecular tumor board at University Cancer Center Hamburg (2016-2022).The oncologist · 2026Article
- MyCODE: a prospective evaluation of lay-language molecular tumor board protocols in precision oncology.The oncologist · 2026Article
- Targeted therapy in patients with genetic tumor syndromes.Medizinische Genetik : Mitteilungsblatt des Berufsverbandes Medizinische Genetik e.V · 2025Article
- Assessing the catchment area of German comprehensive cancer centers by merging geographic healthcare data - an initiative of the ONCOnnect consortium.Journal of cancer research and clinical oncology · 2025Article
- CG>TG mutation frequency as negative predictor of homologous recombination deficiency in ovarian and breast cancer.Communications biology · 2025Article
- Large language models-enabled digital twins for precision medicine in rare gynecological tumors.NPJ digital medicine · 2025Article
- Celebrating Ulrik Ringborg: Multi-Omics-Based Patient Stratification for Precision Cancer Treatment.Biomolecules · 2025Review
- Systematic review and meta-analysis of molecular tumor board data on clinical effectiveness and evaluation gaps.NPJ precision oncology · 2025Article
- Empowering personalized oncology: evolution of digital support and visualization tools for molecular tumor boards.BMC medical informatics and decision making · 2025Article
- Harmonization and standardization of personalized oncology care within the German network for personalized medicine (DNPM): methods of a controlled observational study employing an adapted stepped-wedge design.Frontiers in health services · 2025Article
- Trametinib in combination with hydroxychloroquine or palbociclib in advanced metastatic pancreatic cancer: data from a retrospective, multicentric cohort (AIO AIO-TF/PAK-0123).Journal of cancer research and clinical oncology · 2024Article
- Comprehensive genetic profiling and molecularly guided treatment for patients with primary CNS tumors.NPJ precision oncology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
57 authors.
A L IllertDepartment of Medicine I, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
A StenzingerInstitute of Pathology, Heidelberg University Hospital, Heidelberg, Germany.ORCID 0000-0003-1001-103X
M BitzerDepartment of Internal Medicine I, University Hospital Tübingen, Tübingen, Germany.ORCID 0000-0002-4463-8263
P HorakCenter for Personalized Medicine (ZPM), Heidelberg, Germany.ORCID 0000-0003-4536-9306
V I GaidzikDepartment of Internal Medicine III, University Hospital of Ulm, Ulm, Germany.
Y MöllerCenter for Personalized Medicine (ZPM), Tübingen, Germany.
J BehaCenter for Personalized Medicine (ZPM), Tübingen, Germany.
Ö ÖnerCenter for Personalized Medicine (ZPM), Tübingen, Germany.
F SchmittCenter for Personalized Medicine (ZPM), Tübingen, Germany.
S LaßmannCenter for Personalized Medicine (ZPM), Freiburg, Germany.
S OssowskiCenter for Personalized Medicine (ZPM), Tübingen, Germany.
C P SchaafCenter for Personalized Medicine (ZPM), Heidelberg, Germany.
M HallekDepartment I of Internal Medicine, Medical Faculty and University Hospital Cologne, University of Cologne, Cologne, Germany.
T H BrümmendorfDepartment of Hematology, Oncology, Hemostaseology, and Stem Cell Transplantation, Faculty of Medicine, RWTH Aachen University, Aachen, Germany.ORCID 0000-0002-9677-3723
P AlbersDepartment of Urology, Heinrich-Heine University, Medical Faculty, Düsseldorf, Germany.
T FehmDepartment of Gynecology, Heinrich Heine University Düsseldorf, Düsseldorf, Germany.
P BrossartDepartment of Oncology, Hematology, Stem Cell Transplantation, Cell- and Immunotherapies, Clinical Immunology and Rheumatology, University Hospital Bonn, Bonn, Germany.
H GlimmDepartment of Translational Medical Oncology, National Center for Tumor Diseases (NCT), Dresden, Germany.
D SchadendorfDepartment of Dermatology, University Duisburg-Essen, University Hospital Essen, Essen, Germany.ORCID 0000-0003-3524-7858
A BleckmannDepartment of Medicine A: Hematology, Oncology, and Pneumology, University Hospital Münster (UKM), Münster, Germany.
C H BrandtsUniversity Cancer Center (UCT) Frankfurt-Marburg, University Hospital Frankfurt, Goethe University, Frankfurt, Germany.ORCID 0000-0003-1732-2535
I EspositoInstitute of Pathology, Heinrich-Heine University and University Hospital, Düsseldorf, Germany.
E MackDepartment of Hematology, Oncology and Immunology, University Hospital Marburg and Philipps-University, Marburg, Germany.
C PetersInstitute of Molecular Medicine and Cell Research, University of Freiburg, Freiburg, Germany.
C BokemeyerDepartment of Oncology, Hematology and BMT with section of Pneumology, University of Hamburg, Hamburg, Germany.
S FröhlingCenter for Personalized Medicine (ZPM), Heidelberg, Germany.ORCID 0000-0001-7907-4595
T KindlerUniversity Cancer Center, University Medical Center Mainz, Johannes Gutenberg-University, Mainz, Germany.
H AlgülInstitute for Tumor Metabolism, Klinikum Rechts der Isar, Technical University of Munich, Munich, Germany.ORCID 0000-0002-5067-7031
V HeinemannComprehensive Cancer Center Munich, Klinikum Großhadern, Ludwig Maximilian University of Munich, Munich, Germany.
H DöhnerDepartment of Internal Medicine III, Ulm University Hospital, Ulm, Germany.ORCID 0000-0003-2116-5536
R BargouComprehensive Cancer Center Mainfranken, Uniklinikum Würzburg, Würzburg, Germany.ORCID 0000-0002-1221-7421
V EllenriederDepartment of Gastroenterology, Gastrointestinal Oncology and Endocrinology, University Medical Center Göttingen, Göttingen, Germany.
P HillemannsDepartment of Gynecology and Obstetrics, Hannover Medical School, Hannover, Germany.
F LordickComprehensive Cancer Center Central Germany and University Cancer Center Leipzig,, University Medicine Leipzig, Leipzig, Germany.
A HochhausComprehensive Cancer Center Central Germany and Department of Hematology and Internal Oncology, Universitätsklinikum Jena, Jena, Germany.
M W BeckmannUniversity Hospital Erlangen, Department of Obstetrics and Gynecology, Friedrich-Alexander-Universität Erlangen, Erlangen, Germany.
T PukropDepartment of Internal Medicine III, Hematology and Oncology, University Hospital Regensburg, Regensburg, Germany.
M TrepelDepartment of Hematology and Medical Oncology, Augsburg University Hospital, Augsburg, Germany.
L SundmacherDepartment of Health Services Management, Ludwig-Maximilians-Universität, Munich, Germany.
S WesselmannDeutsche Krebsgesellschaft (DKG), Berlin, Germany.
G NettekovenDeutsche Krebshilfe, Bonn, Germany.
F KohlhuberDeutsche Krebshilfe, Bonn, Germany.
O HeinzeDepartment Medical Information Systems, University Hospital Heidelberg, Heidelberg, Germany.
J BudcziesInstitute of Pathology, Heidelberg University Hospital, Heidelberg, Germany.ORCID 0000-0002-6668-5327
M WernerCenter for Personalized Medicine (ZPM), Freiburg, Germany.
K NikolaouDepartment of Diagnostic and Interventional Radiology, Eberhard Karls University Tübingen, Tübingen, Germany.
A J BeerDepartment of Nuclear Medicine, Ulm University Hospital, Ulm, Germany.
G TabatabaiDepartment of Neurology and Interdisciplinary Neuro-Oncology, Center for Neuro-Oncology, University Hospital Tübingen, Tübingen, Germany.
W WeichertCenter for Personalized Medicine (ZPM), Klinikum rechts der Isar, Technical University of Munich, Munich, Germany.
U KeilholzCharité Comprehensive Cancer Center, Charité, Berlin, Germany.
M BoerriesCenter for Personalized Medicine (ZPM), Freiburg, Germany.
O KohlbacherCenter for Personalized Medicine (ZPM), Tübingen, Germany.ORCID 0000-0003-1739-4598
J DuysterDepartment of Medicine I, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
R ThimmeCenter for Personalized Medicine (ZPM), Freiburg, Germany.ORCID 0000-0003-1417-4135
T SeufferleinCenter for Personalized Medicine (ZPM), Ulm, Germany.
P SchirmacherInstitute of Pathology, Heidelberg University Hospital, Heidelberg, Germany.
N P MalekDepartment of Internal Medicine I, University Hospital Tübingen, Tübingen, Germany. nisar.malek@med.uni-tuebingen.de.
Funding
Deutsche Krebshilfe (German Cancer Aid) Mildre-Scheel-Professorship
Abstract
PubMed holds no abstract for this paper.
Indexed as
Precision MedicineTranslational Research, BiomedicalHumansPatient CareTranslational Science, Biomedical
Identifiers
PMID
37280276What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.